PARIS, France and TARRYTOWN, NY, USA I 6, 2024 I The European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic esophagitis ...
Leads Biolabs grants Oblenio Bio an exclusive option to license LBL-051, a first-in-class CD19xBCMAxCD3 tri-specific T-cell engager antibody ...
SEOUL, South Korea I November 6, 2024 I Hanmi Pharm. Co., Ltd. has announced promising research results for its novel obesity treatment, HM17321. This groundbreaking drug not only augments fat loss ...
November 04, 2024 I Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK ...
After 28 Days of Dosing with Oral Tablet of VK2735 Encouraging Tolerability Through 100 mg Daily Dosing with Oral VK2735; Mild GI-Related Adverse Event Profile Updated Results from VENTURE Phase 2 ...
Research collaboration to leverage Surrozen’s antibody research capabilities and expertise to discover a potential first in class treatment for patients with Idiopathic Pulmonary Fibrosis SOUTH SAN ...
CARLSBAD, CA, USA I 4, 2024 I Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has ...
BRISBANE, Australia & CAMBRIDGE, MA, USA I8, 2024 I Vaxxas, a clinical-stage biotechnology company commercializing a novel ...
SHANGHAI, China and CLINTON, NJ, USA I 4, 2024 I HuidaGene Therapeutics ("HuidaGene"), a global clinical-stage biotechnology company, announced that ...
PASADENA, CA, USA I November 04, 2024 I Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the ...